CRISPR-Mediated Epigenetic Reprogramming Attenuates Inflammatory Cell Injury Through Targeted Transcriptional Modulation: An Experimental in Vitro and in Vivo Study
Advanced Journal of Biomedicine & Medicine · 2026
DOI: 10.18081/ajbm.2026.3.294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Journal of Biomedicine & Medicine, 2026. Verfasst von Hiroshi Takamura und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Persistent NF-κB-driven inflammatory transcription promotes inflammasome activation, oxidative stress, mitochondrial dysfunction, and regulated cell death. Although CRISPR-based epigenome editing enables locus-specific transcriptional regulation without permanent modification of the underlying DNA sequence, its capacity to protect against inflammatory cell injury in vivo remains incompletely defined.
Objective
To determine whether dCas9-KRAB-mediated epigenetic repression of Nfkb1 attenuates inflammatory cell injury and to define the molecular mechanisms linking targeted chromatin remodeling with cytoprotection.
Method
A nuclease-inactive CRISPR/dCas9-KRAB system targeting the Nfkb1 regulatory region was evaluated in LPS-stimulated RAW 264.7 macrophages and a murine model of systemic LPS-induced inflammation. Non-targeting sgRNA served as the CRISPR control. Target engagement was assessed by RT-qPCR, immunoblotting, and H3K9me3 ChIP-qPCR. Inflammatory cytokines, NLRP3/caspase-1/GSDMD signaling, intracellular and mitochondrial reactive oxygen species, NRF2-associated antioxidant responses, mitochondrial membrane potential, cell viability, membrane injury, apoptosis, and pyroptosis-associated endpoints were evaluated. In vivo outcomes included circulating cytokines, histopathological injury, neutrophilic infiltration, tissue inflammasome signaling, TUNEL positivity, biochemical indices of organ injury, and survival.
Results
Targeted dCas9-KRAB repression increased H3K9me3 enrichment at the Nfkb1 regulatory locus and reduced Nfkb1 transcription by 64.8% compared with the LPS + non-targeting CRISPR group (P
Zitieren
APA
Takamura, H., Nakamura, Y., Fujimoto, R., Morita, K., Shimizu, A., & Yamamoto, T. (2026). CRISPR-Mediated Epigenetic Reprogramming Attenuates Inflammatory Cell Injury Through Targeted Transcriptional Modulation: An Experimental in Vitro and in Vivo Study. Advanced Journal of Biomedicine & Medicine. https://doi.org/10.18081/ajbm.2026.3.294
Vancouver
Takamura H, Nakamura Y, Fujimoto R, Morita K, Shimizu A, Yamamoto T. CRISPR-Mediated Epigenetic Reprogramming Attenuates Inflammatory Cell Injury Through Targeted Transcriptional Modulation: An Experimental in Vitro and in Vivo Study. Advanced Journal of Biomedicine & Medicine. 2026. doi:10.18081/ajbm.2026.3.294
BibTeX
@article{Takamura2026,
author = {Takamura, Hiroshi and Nakamura, Yuki and Fujimoto, Rina and Morita, Keisuke and Shimizu, Ayaka and Yamamoto, Takeshi},
title = {CRISPR-Mediated Epigenetic Reprogramming Attenuates Inflammatory Cell Injury Through Targeted Transcriptional Modulation: An Experimental in Vitro and in Vivo Study},
journal = {Advanced Journal of Biomedicine & Medicine},
year = {2026},
doi = {10.18081/ajbm.2026.3.294}
}
EUVIMED